Myriad Genetics (MYGN) Shares Plunge 5.99% Amid Sector Weakness in Genetic Testing, Biotech Stocks

Myriad Genetics (MYGN) shares plunged 5.99% intraday on Sept. 12, 2025, marking their lowest level since September 2025 amid sustained selling pressure. The stock closed down 5.73% for the session, reflecting a sharp reversal in momentum after months of sideways trading.

Analysts noted the decline occurred in the absence of direct company-specific catalysts, such as earnings reports, product launches, or regulatory updates. The move appears linked to broader sector weakness in genetic testing and biotech stocks, which have faced renewed scrutiny over valuation metrics and reimbursement challenges. Myriad’s market cap contraction aligns with industry trends, as investors reassess long-term growth assumptions for diagnostic innovators.

With no material news from the company or its peers influencing the trade, the selloff highlights the sector’s vulnerability to macroeconomic headwinds. Rising interest rates and shifting insurance coverage policies continue to pressure firms reliant on recurring revenue models. While Myriad maintains a dominant position in hereditary cancer testing, its business model remains exposed to pricing pressures and competitive threats in the rapidly evolving genetic diagnostics landscape.

Short-term technical indicators suggest further consolidation is likely before a potential rebound. However, institutional investors remain cautious, with reduced open interest in derivative contracts indicating diminished speculative positioning. The stock’s performance will hinge on broader market sentiment and any upcoming developments in healthcare policy that could reshape reimbursement frameworks for genetic tests.